Welcome to our dedicated page for Mosaic Immunoengineering SEC filings (Ticker: CPMV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
headquartered in carlsbad, california, patriot scientific corporation provides data sharing and secure data solutions for a connected world. patriot scientific addresses the expanding market opportunities in the healthcare, justice and public safety industries through its wholly owned subsidiary patriot data solutions group, inc. these growth activities are funded with revenues generated, in a large part, from the continuing successful moore microprocessor patent(tm) portfolio licensing partnership with the tpl group. patriot scientific's integrated core intelligence solution addresses the critical data/information sharing needs of the healthcare industry, the department of homeland security, the department of justice, and federal, state, and local public safety and law enforcement agencies.Mosaic ImmunoEngineering, Inc. notified the SEC that it could not timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 because additional time, resources and effort are required to complete financial close and reporting procedures.
The company states it expects to file the Form 10-K no later than the fifteenth calendar day following the prescribed due date.
Mosaic ImmunoEngineering, Inc. reported a Q3 2025 net loss of $165,361, improving from a $186,730 loss a year earlier, as both research and development and general and administrative costs declined. For the first nine months of 2025, the company recorded a net loss of $518,709, versus $768,939 in the prior-year period, reflecting lower payroll and operating expenses.
Cash and cash equivalents were only $31,761 as of September 30, 2025, against total liabilities of $7,362,181 and a stockholders’ deficit of $7,306,883, and management states there is substantial doubt about the company’s ability to continue as a going concern without new capital. Mosaic remains a development-stage oncology-focused biotech, has not generated revenue, and is relying on future financings while its previous $15.0 million asset acquisition term sheet with Oncotelic has expired. As of November 19, 2025, 7,242,137 common shares were outstanding.
Mosaic ImmunoEngineering filed a Form 12b-25, notifying a late filing of its Quarterly Report on Form 10-Q. The company cites the need for additional time, resources, and effort to complete financial reporting and close procedures. It expects to file the Form 10-Q as soon as possible, and on or before the fifth calendar day following the prescribed due date.